The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

Table 2

Patient and pathological tumor characteristics between BCG/IFN failures and nonfailures.

	Failures		Nonfailures		value
No	25	56.8%	19	43.2%
Male	18	40.9%	17	38.6%	0.15
Female	7	15.9%	2	4.5%	0.15
Time to BCG failure
<6 months	16	36.4%	4	9.1%	0.0046
6–12 months	6	13.6%	6	13.6%	0.5
12–24 months	1	2.3%	5	11.4%	0.84
>24 months	6	13.6%	4	9.1%	0.21
Pathology at induction
Tis	7	15.9%	8	18.2%	0.33
Ta	10	22.7%	5	11.4%	0.27
T1	8	18.2%	6	13.6%	0.44
Grade at induction
HG	22	50.0%	17	38.6%	0.93
LG	3	6.8%	2	4.5%	0.93
Tumor size
<1 cm	7	15.9%	6	13.6%	0.79
1–5 cm	16	36.4%	12	27.3%	0.95
>5 cm	2	4.5%	1	2.3%	0.72
Multifocality
Yes	11	25.0%	6	13.6%	0.4
Hx smoking	16	36.4%	12	27.3%	0.95